Drug Information

General Information
Drug ID
DR00168
Drug Name
Latanoprost
Synonyms
AR-202; Catioprost; Isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinor-prost-5-en-1-oate; Isopropyl (5Z,9alpha,11alpha,15R)-9,11,15-trihydroxy-17-phenyl-18,19,20-trinorprost-5-en-1-oate; Isopropyl (Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-((3R)-3-hydroxy-5-phenylpentyl)cyclopentyl)-5-heptenoate; L1167_SIGMA; Latanoprost (JAN/USAN/INN); Latanoprost free acid; Nova-21027; PHXA-41; PhXA34 [as 15(R,S)-isomer]; PhXA41; Propan-2-yl (5Z)-7-{(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl}hept-5-enoate; Propan-2-yl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl]hept-5-enoate; XA-41; XA41; Xalatan; Xalatan (TN)
Drug Type
Small molecular drug
Indication Ocular hypertension [ICD11: 9C61.01] Approved [1]
Open angle glaucoma [ICD11: 9C61] Approved [1]
Therapeutic Class
Antihypertensive Agents
Structure
3D MOL 2D MOL
Formula
C23H34O5
Canonical SMILES
C1C(C(C(C1O)CC=CCCCC(=O)O)CCC(CCC2=CC=CC=C2)O)O
InChI
InChI=1S/C23H34O5/c24-18(13-12-17-8-4-3-5-9-17)14-15-20-19(21(25)16-22(20)26)10-6-1-2-7-11-23(27)28/h1,3-6,8-9,18-22,24-26H,2,7,10-16H2,(H,27,28)/b6-1-/t18-,19+,20+,21-,22+/m0/s1
InChIKey
HNPFPERDNWXAGS-NFVOFSAMSA-N
CAS Number
CAS 130209-82-4
Pharmaceutical Properties Molecular Weight 390.5 Topological Polar Surface Area 98
Heavy Atom Count 28 Rotatable Bond Count 12
Hydrogen Bond Donor Count 4 Hydrogen Bond Acceptor Count 5
XLogP
3.1
PubChem CID
6441636
PubChem SID
103286196 , 114563873 , 118842177 , 11968815 , 135124962 , 135611159 , 135650508 , 142805251 , 14829941 , 164228148 , 198989236 , 224405006 , 227536373 , 241078678 , 24724524 , 252421418 , 252457330 , 252562137 , 29217578 , 43034285 , 56311305 , 57369233 , 75823169
ChEBI ID
ChEBI:6384
TTD Drug ID
D0C6NM
DT(s) Transporting This Drug OATP2A1 Transporter Info Organic anion transporting polypeptide 2A1 Substrate [2]
OATP2B1 Transporter Info Organic anion transporting polypeptide 2B1 Substrate [2]
References
1 Latanoprost was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019)
2 The prostaglandin transporter OATP2A1 is expressed in human ocular tissues and transports the antiglaucoma prostanoid latanoprost. Invest Ophthalmol Vis Sci. 2010 May;51(5):2504-11.

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.